Editor's Note: For Use by Reporters in the European Union Only. JANUVIA(R)(1) (sitagliptin), Merck, Sharp & Dohme's treatment for patients with type 2 diabetes, today received a positive opinion from ...

In one quick announcement Monday, Merck's ($MRK) diabetes drug Januvia became the drug to beat in its class. New study data could boost Januvia's sales by 10% in 2020 ...

Januvia and Janumet are two blockbuster drugs in Merck & Co.’s (MRK) diabetes franchise. The drugs are used to lower the blood sugar level in patients with type-2 diabetes. The combined sales for ...

The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions. An evaluation of results ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

NEW YORK, Oct 17 (Reuters) - Merck & Co said on Wednesday U.S. regulators have approved use of its Januvia diabetes drug in new combinations with other treatments, but noted reports of serious ...

Merck Sharp & Dohme has won expanded use from the European Commission to market its new diabetes therapy Januvia (sitagliptin). It is the only drug within the DPP-4 class of medicines to have received ...

(Reuters) - Merck & Co Inc (MRK) reported lower sales of its Januvia diabetes treatment, fresh evidence its biggest product is losing ground to newer drugs, and also spooked investors with falling ...